Aclarion Inc. has announced a strategic dual-approach to its corporate governance and commercial growth, combining a new defensive shareholder measure with an optimistic roadmap for its AI-driven medical technology.
The company board of directors has officially adopted a limited-duration stockholder rights plan. This measure is designed to protect the company and its investors from any person or group seeking to gain control of Aclarion through open market accumulation without paying an appropriate control premium. Key details of the rights plan include:
- The plan is set to expire in one year, on March 18, 2027.
- The rights will generally become exercisable if a person or group acquires 10 percent or more of the company common stock.
- The move is intended to ensure the board has sufficient time to make informed decisions that are in the best long-term interests of all stockholders.
Alongside this defensive update, Aclarion CEO Brent Ness issued a letter to shareholders detailing the company strategic progress and upcoming catalysts for 2026. The letter highlights the momentum of the Nociscan platform, which uses proprietary algorithms to help physicians identify the location of chronic low back pain. Major milestones and financial updates include:
- An initial readout of the CLARITY clinical trial is expected in the fourth quarter of 2026.
- The company is actively pursuing reimbursement coverage from regional insurance providers in the United States and advancing initiatives in the United Kingdom.
- Aclarion reports a strong balance sheet with a cash runway extending into 2028, providing stability for continued execution of its clinical and commercial goals.
- The company continues to expand commercial engagement with physicians and imaging centers to drive broader adoption of its technology.
By implementing the rights plan while simultaneously hitting clinical and financial benchmarks, Aclarion aims to protect its current valuation while positioning its diagnostic technology for long-term scalability in the healthcare market.
Sources: Press Release, Press Release
